Yaman Lu
Overview
Explore the profile of Yaman Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mosley R, Lu Y, Olson K, Machhi J, Yan W, Namminga K, et al.
Front Cell Neurosci
. 2019 Oct;
13:421.
PMID: 31619964
A paradigm shift has emerged in Parkinson's disease (PD) highlighting the prominent role of CD4 Tregs in pathogenesis and treatment. Bench to bedside research, conducted by others and our own...
12.
Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Zhang G, et al.
J Neuroinflammation
. 2018 May;
15(1):137.
PMID: 29729668
Background: The mixed lineage kinase type 3 inhibitor URMC-099 facilitates amyloid-beta (Aβ) clearance and degradation in cultured murine microglia. One putative mechanism is an effect of URMC-099 on Aβ uptake...
13.
Kiyota T, Machhi J, Lu Y, Dyavarshetty B, Nemati M, Yokoyama I, et al.
J Neuroimmunol
. 2018 Mar;
319:80-92.
PMID: 29573847
We investigated the effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on behavioral and pathological outcomes in Alzheimer's disease (AD) and non-transgenic mice. GM-CSF treatment in AD mice reduced brain amyloidosis,...
14.
Gendelman H, Zhang Y, Santamaria P, Olson K, Schutt C, Bhatti D, et al.
NPJ Parkinsons Dis
. 2017 Jun;
3:10.
PMID: 28649610
A potential therapeutic role for immune transformation in Parkinson's disease evolves from more than a decade of animal investigations demonstrating regulatory T cell (Treg) nigrostriatal neuroprotection. To bridge these results...
15.
Embury C, Dyavarshetty B, Lu Y, Wiederin J, Ciborowski P, Gendelman H, et al.
J Neuroimmune Pharmacol
. 2016 Dec;
12(2):340-352.
PMID: 27966067
Amyloid-ß (Aß) precursor protein (APP) metabolism engages neuronal endolysosomal pathways for Aß processing and secretion. In Alzheimer's disease (AD), dysregulation of APP leads to excess Aß and neuronal dysfunction; suggesting...
16.
Dong W, Embury C, Lu Y, Whitmire S, Dyavarshetty B, Gelbard H, et al.
J Neuroinflammation
. 2016 Jul;
13(1):184.
PMID: 27401058
Background: Amyloid-β (Aβ)-stimulated microglial inflammatory responses engage mitogen-activated protein kinase (MAPK) pathways in Alzheimer's disease (AD). Mixed-lineage kinases (MLKs) regulate upstream MAPK signaling that include p38 MAPK and c-Jun amino-terminal...
17.
Kiyota T, Zhang G, Morrison C, Bosch M, Weir R, Lu Y, et al.
Mol Ther
. 2015 Aug;
23(11):1712-1721.
PMID: 26227349
Modulation of the amyloid-β (Aβ) trafficking pathway heralds a new therapeutic frontier for Alzheimer's disease (AD). As CD74 binds to the amyloid-β precursor protein (APP) and can suppresses Aβ processing,...
18.
Senanayake T, Lu Y, Bohling A, Raja S, Band H, Vinogradov S
Pharm Res
. 2014 Jan;
31(6):1605-15.
PMID: 24452808
Purpose: Current cancer chemotherapy is gradually shifting to the application of drug combinations that prevent development of drug resistance. Many anticancer drugs have poor solubility and limited oral bioavailability. Using...
19.
Wen H, Lu Y, Yao H, Buch S
PLoS One
. 2011 Jul;
6(6):e21707.
PMID: 21738771
Despite the advent of antiretroviral therapy, complications of HIV-1 infection with concurrent drug abuse are an emerging problem. Morphine, often abused by HIV-infected patients, is known to accelerate neuroinflammation associated...
20.
Yang Y, Yao H, Lu Y, Wang C, Buch S
PLoS One
. 2010 Oct;
5(10):e13427.
PMID: 20976166
It is becoming widely accepted that psychoactive drugs, often abused by HIV-I infected individuals, can significantly alter the progression of neuropathological changes observed in HIV-associated neurodegenerative diseases (HAND). The underlying...